Recce Pharmaceuticals doses first patients over 15 minutes in R327 UTI/urosepsis trial
Menu
Recce Pharmaceuticals Ltd (ASX:RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health threat of antibiotic-resistant superbugs.